| Assessment Status | Rapid Review Complete |
| HTA ID | 20006 |
| Drug | Avatrombopag |
| Brand | Doptelet® |
| Indication | For the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. |
| Assessment Process | |
| Rapid review commissioned | 11/02/2020 |
| Rapid review completed | 02/04/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that avatrombopag be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement September 2020
